Current through September 16, 2024
1. A pharmacy
engaged in the practice of compounding and dispensing parenteral solutions
shall have on the premises or readily accessible:
(a) A record for each patient being treated
with parenteral therapy;
(b) A
summary of the most recent hospitalization of the patient or the patient's
medical history; and
(c) Any notes
taken by the pharmacist concerning the progress of the patient which document
any contact with the patient or the practitioner concerning the parenteral
therapy.
2. In addition
to any other requirements for keeping records, the following records must be
maintained in the pharmacy:
(a) Records
concerning any prescriptions and medical supplies furnished to the
patient.
(b) Information relevant
to the patient's parenteral therapy, including, but not limited to:
(1) The patient's name, age, height, weight,
sex and address and the telephone number of the location where the patient is
receiving parenteral therapy;
(2)
The diagnosis of the patient; and
(3) The patient's history of medication,
including his or her current regimen concerning diet and medication and any
allergies to drugs or food.
(c) Data of a laboratory relevant to the
parenteral therapy.
(d) If the
patient is using a parenteral solution in the patient's home, in a facility for
the dependent or in a medical facility which does not furnish the parenteral
solution from a pharmacy located in that medical facility, records indicating
that the care of the patient is coordinated by the pharmacy, practitioner and
nursing personnel before the administration of the parenteral solution,
including:
(1) Documentation of all orders
for medication, laboratory tests or other treatment related to the medication
of the patient.
(2) Documentation
of all orders given by a practitioner which were communicated to nursing
personnel by a pharmacist.
(3)
Documentation that a total assessment of the patient has been
performed.
(4) Documentation that a
plan for the parenteral therapy of the patient has been developed by the
pharmacy. The plan must include:
(I) The
identification of any problem related to a drug that is administered to the
patient; and
(II) Any suggested
solution for that problem and the monitoring of the results of the
therapy.
3. As used in this section, "total
assessment" means an evaluation of the circumstances of the administration of
parenteral therapy to a patient in the patient's home, in a facility for the
dependent or in a medical facility which does not furnish the parenteral
solution from a pharmacy located within that medical facility that includes a
review of:
(a) The state of the disease of
the patient;
(b) The regimen of
medication of the patient;
(c) The
medical history of the patient;
(d)
Any therapies other than parenteral therapy administered to the patient;
and
(e) If the patient is using the
parenteral solution in the patient's home, the ability of the patient to
receive parenteral therapy in his or her home.
Added to NAC by Bd. of
Pharmacy, eff. 8-14-87; A 7-7-94
NRS
639.070,
639.2807
